CELCUITY INC Share Price Today: Live Updates & Key Insights

CELCUITY INC share price today is $106.41, up -6.15%. The stock opened at $110.09 against the previous close of $112.99, with an intraday high of $111.73 and low of $103.6675.

CELCUITY INC Share Price Chart

CELCUITY INC

us-stock
To Invest in {{usstockname}}
us-stock

CELCUITY INC Share Price Performance

$106.41 -0.0615(-6.15%) CELC at 23 Mar 2026 12:25 PM Biotechnology
Lowest Today 103.6675
Highest Today 111.73
Today’s Open 110.09
Prev. Close 112.99
52 Week High 120.32
52 Week Low 7.58
Day’s Range: Low 103.6675 High 111.73
52-Week Range: Low 7.58 High 120.32
1 day return -
1 Week return -7.71
1 month return +0.98
3 month return +4.97
6 month return +102.21
1 year return +873.02
3 year return +963.79
5 year return +625.44
10 year return -

CELCUITY INC Institutional Holdings

Baker Bros Advisors LP 17.11

NEA Management Company, LLC 7.64

venBio Select Advisor LLC 6.72

Perceptive Advisors LLC 6.39

Vanguard Group Inc 4.93

BlackRock Inc 4.86

Deerfield Management Co 3.70

Morgan Stanley - Brokerage Accounts 3.27

Vanguard Total Stock Mkt Idx Inv 2.87

Soleus Capital Management, L.P. 2.55

TANG CAPITAL MANAGEMENT LLC 2.49

State Street® SPDR® S&P® Biotech ETF 2.07

UBS Group AG 1.85

Geode Capital Management, LLC 1.80

Sio Capital Management, LLC 1.70

iShares Russell 2000 ETF 1.69

State Street Corp 1.56

Holocene Advisors, LP 1.50

AllianceBernstein L.P. 1.41

Apis Capital Advisors, LLC 1.30

T. Rowe Price Associates, Inc. 1.29

T. Rowe Price Health Sciences 1.27

RTW INVESTMENTS, LLC 1.19

Artisan Partners Limited Partnership 1.18

Vanguard Institutional Extnd Mkt Idx Tr 0.84

Artisan International Small-Mid Investor 0.72

Artisan Non-U.S. Small-Mid Growth Comp 0.72

Fidelity Small Cap Index 0.68

Eventide Healthcare & Life Sciences I 0.68

Belfius Equities Cure C Cap 0.65

iShares Russell 2000 Growth ETF 0.55

US Small-Cap Growth II Equity Comp 0.43

T. Rowe Price New Horizons 0.43

Candriam Eqs L Biotech C USD Cap 0.42

AB Small Cap Growth A 0.41

Fidelity Extended Market Index 0.40

State St Russell Sm/Mid Cp® Indx SL Cl I 0.40

Schwab US Small-Cap ETF™ 0.38

Vanguard Russell 2000 ETF 0.33

MEDICAL BioHealth EUR Acc 0.32

CELCUITY INC Market Status

Strong Buy: 5

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

CELCUITY INC Fundamentals

Market Cap 4906.60 M

PB Ratio 41.9501

PE Ratio 0.0

Enterprise Value 4771.97 M

Total Assets 245.12 M

Volume 1862820

CELCUITY INC Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-56511990 -56.5M, FY22:-41348989 -41.3M, FY21:-30564381 -30.6M, FY20:-9088704 -9.1M, FY19:-7020527 -7.0M

Quarterly Revenue Q3/2025:154000 0.2M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-41000 -0.0M, Q2/2025:-40000 -0.0M, Q1/2025:-37000 -0.0M, Q3/2024:null 0.0M, Q2/2024:-31115 -0.0M

Quarterly Net worth Q3/2025:-43804000 -43.8M, Q2/2025:-45268000 -45.3M, Q1/2025:-36997000 -37.0M, Q3/2024:-29791789 -29.8M, Q2/2024:-23721820 -23.7M

About CELCUITY INC & investment objective

Company Information Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). It also engages in developing of CELsignia diagnostic platform. The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is based in Minneapolis, Minnesota.

Organisation Biotechnology

Employees 87

Industry Biotechnology

CEO Mr. Brian F. Sullivan

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

CELCUITY INC FAQs

What is the share price of CELCUITY INC today?

The current share price of CELCUITY INC is $106.41.

Can I buy CELCUITY INC shares in India?

Yes, Indian investors can buy CELCUITY INC shares by opening an international trading and demat account with Motilal Oswal.

How to buy CELCUITY INC shares in India?

You can easily invest in CELCUITY INC shares from India by:

Can I buy fractional shares of CELCUITY INC?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of CELCUITY INC?

CELCUITY INC has a market cap of $4906.60 M.

In which sector does CELCUITY INC belong?

CELCUITY INC operates in the Biotechnology sector.

What documents are required to invest in CELCUITY INC stocks?

To invest, you typically need:

What is the PE and PB ratio of CELCUITY INC?

The PE ratio of CELCUITY INC is N/A and the PB ratio is 41.95.